E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of cervical, vulvar, vaginal, and anal cancers and related precancers, and anogenital warts caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58. |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of human papillomavirus (HPV) infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10063001 |
E.1.2 | Term | Human papilloma virus infection |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In 9- to 26-year-old female and male participants:
To demonstrate that the 9vHPV vaccine is immunogenic |
|
E.2.2 | Secondary objectives of the trial |
In 9- to 26-year-old female and male participants:
- To evaluate the safety of 9vHPV vaccine.
- To summarize geometric mean titers (GMTs) at Day 1 and at 4 weeks post Dose 3 of 9vHPV vaccine. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- In good physical health
- Participants 9 to 15 years of age: has not had coitarche and do not plan on becoming sexually active during the study
- Participants 16 to 26 year of age: has never had Papanicolaou (Pap) testing or has had only normal Pap test results. Has a lifetime history of ≤4 male and/or female sexual partners.
- Female participants 16 to 26 years of age: has not had sex with males or has had sex with males and used effective contraception, and understands and agrees that during the study she should not have sexual intercourse with males without effective contraception (rhythm method, withdrawal, and emergency contraception are not acceptable methods of contraception per-protocol). |
|
E.4 | Principal exclusion criteria |
- Known allergy to any vaccine component, including aluminum, yeast, or BENZONASE™
- History of severe allergic reaction that required medical intervention
- Has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
- Concurrently enrolled in clinical studies of investigational agents
- Immunocompromised or has been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
- Had a splenectomy
- User of recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
- History of a positive test for HPV
- Male participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata) or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer.
- Female participants 16 to 26 years of age: history of an abnormal cervical biopsy result (showing cervical intraepithelial neoplasia or worse).
- Female participants 16 to 26 years of age: history of HPV-related external genital lesions (e.g., condyloma acuminata, or vulvar intraepithelial neoplasia) or external genital cancer, HPV-related vaginal lesions (e.g., condyloma acuminata, or vaginal intraepithelial neoplasia) or vaginal cancer, or HPV-related anal lesions (e.g., condyloma acuminata, or anal intraepithelial neoplasia) or anal cancer.
- Female participants: pregnant as determined by a serum pregnancy test or urine pregnancy test that is sensitive to 25 mIU/mL beta human chorionic gonadotropin (β-hCG).
- Female participants: expecting to donate eggs during the study.
- Receiving or has received a prohibited immunosuppressive therapy in the year prior to the study
- Received any immune globulin product or blood-derived product within the 3 months prior to the Day 1 vaccination, or plans to receive any such product during the study
- Received inactivated or recombinant vaccines within 14 days prior to the Day 1 vaccination or has received live vaccines within 21 days prior to the Day 1 vaccination
- Received a marketed HPV vaccine, or has participated in an HPV vaccine clinical study and has received either active agent or placebo
- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
4 weeks postdose 3 (Month 7) |
|
E.5.2 | Secondary end point(s) |
1. Percentage of Participants with a Solicited Injection-site Adverse Event
2. Percentage of Participants with a Solicited Systemic Adverse Event
3. Percentage of Participants with a Vaccine-related Serious Adverse Event
4. Geometric Mean Titers of Serotype-specific Antibodies
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Up to 5 days after any vaccination
2. Up to 15 days after any vaccination
3. Up to 4 weeks postdose 3 (Month 7)
4. Day 1 (predose) and 4 weeks postdose 3 (Month 7) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The overall study ends when the last participant completes the last study-related phone-call or visit, withdraws from the study or is lost to follow-up . For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last serology assay result. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 11 |